How many Risankizumab clinical trials are there?

82 Risankizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 12 are actively recruiting participants. 52 are marked completed.

Are Risankizumab clinical trials recruiting in 2026?

Yes — 12 Risankizumab trials are actively recruiting in 2026, with 170 U.S. sites across 35 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Risankizumab being studied for?

Risankizumab is being studied for Psoriasis, Healthy Volunteers, Crohn's Disease, Ulcerative Colitis (UC), Crohn Disease and 27 more. The trials are grouped by indication on this page.

What phase is Risankizumab in?

Risankizumab clinical trials span 8 Phase 4, 33 Phase 3, 15 Phase 2, 17 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Risankizumab clinical trials?

The lead sponsor across the most Risankizumab trials is AbbVie, with 15 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Risankizumab Clinical Trials (2026): 82 Studies for Psoriasis & Healthy Volunteers

Creator: Hipa.ai Research
Published: 2026-05-08T19:15:50.599Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 18, 2026.

82 Risankizumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 24 indications (including Psoriasis & Healthy Volunteers) and 24,412 total planned enrollment. 33 Phase 3 Risankizumab trials and 15 Phase 2, 8 Phase 4 are listed. 18 Risankizumab clinical trials are actively recruiting at 170 U.S. sites across 35 states. Most recent activity: NCT07071519 (Jul 2034).

Where to Participate: All Risankizumab Trial Sites in the U.S. (170 sites across 35 states)

Every actively recruiting Risankizumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Digestive Health Specialists /ID# 266216	Dothan36301	NCT06548542	Map
AL	Digestive Health Specialists of the Southeast	Dothan36305	NCT07499232	Map
AL	East View Medical Research /ID# 270377	Mobile36606	NCT06548542	Map
AZ	Clinical Site	Avondale85392	NCT06641089	Map
AZ	Clinical Site	Mesa85210	NCT06641089	Map
AZ	Clinical Site	Phoenix85032	NCT06641089	Map
AZ	Phoenix Children's Hospital /ID# 255766	Phoenix85016-7710	NCT05995353	Map
AZ	Phoenix Children's Hospital /ID# 273015	Phoenix85016	NCT07071519	Map
AZ	Clinical Site	Scottsdale85260	NCT06641089	Map
AZ	GI Alliance - Sun City	Sun City85351	NCT06249555	Map
AZ	Clinical Site	Tucson85748	NCT06641089	Map
AR	Clinical Site	Jonesboro72401	NCT06641089	Map
AR	Arkansas Children's Hospital /ID# 255762	Little Rock72202	NCT05995353	Map
AR	Arkansas Children's Hospital /ID# 258776	Little Rock72202	NCT06100744	Map
CA	Clinnova Research	Anaheim92805	NCT07499232	Map
CA	Southern California Res. Ctr /ID# 265549	Coronado92118	NCT06548542	Map
CA	Newport Huntington Medical Group /ID# 272764	Huntington Beach92648-5994	NCT06865105	Map
CA	Clinical Site	La Jolla92037	NCT06641089	Map
CA	UC San Diego Health System /ID# 265565	La Jolla92037	NCT06548542	Map
CA	United Gastroenterologists	Los Alamitos90720	NCT07499232	Map
CA	TLC Clinical Research Inc	Los Angeles90048	NCT07499232	Map
CA	UCSF Benioff Children's Hospital - Oakland /ID# 258327	Oakland94609	NCT05995353	Map
CA	Clinical Site	Pomona91767	NCT06641089	Map
CA	uc davis medical center - patient support services building /ID# 265554	Sacramento95817	NCT06548542	Map
CA	Clinical Applications Laboratories - San Diego - 3rd Avenue /ID# 267391	San Diego92103	NCT06548542	Map
CA	Clinical Site	San Diego92108	NCT06641089	Map
CA	Rady Children's Hospital /ID# 271873	San Diego92123	NCT07071519	Map
CA	University of California San Francisco - Mission Bay /ID# 273022	San Francisco94158	NCT07071519	Map
CA	Clinical Site	Santa Monica90404	NCT06641089	Map
CA	Clinical Site	Thousand Oaks91360	NCT06641089	Map
CA	Clinical Site	Upland91786	NCT06641089	Map
CO	Children's Hospital Colorado - Aurora /ID# 255764	Aurora80045	NCT05995353	Map
CO	Peak Gastroenterology Associates	Colorado Springs80907	NCT07499232	Map
CO	Peak Gastroenterology Associates - Colorado Springs - North Cascade Avenue /ID# 265557	Colorado Springs80907	NCT06548542	Map
CT	Danbury Hospital, Western Connecticut Health Network /ID# 265556	Danbury06810	NCT06548542	Map
CT	Yale University School of Medicine /ID# 266786	New Haven06510	NCT06548542	Map
DC	Childrens National Medical Center /ID# 259284	Washington D.C.20010-2916	NCT06100744	Map
FL	Clinical Site	Avon Park33825	NCT06641089	Map
FL	Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 273085	Avon Park33825	NCT06865105	Map
FL	Clinical Research Of West Florida - Phase I Unit /ID# 273198	Clearwater33765	NCT06865105	Map
FL	Clinical Site	Clearwater33765	NCT06641089	Map
FL	Novum Research /ID# 278128	Clermont34711	NCT06548542	Map
FL	University of Florida College of Medicine /ID# 266930	Gainesville32610	NCT06548542	Map
FL	Clinical Site	Hialeah33016	NCT06641089	Map
FL	Joe Dimaggio Children's Hospital Hollywood /ID# 260634	Hollywood33021	NCT06100744	Map
FL	Nature Coast Clinical Research - Inverness /ID# 265874	Inverness34452-4717	NCT06548542	Map
FL	Atlantic Medical Research /ID# 266207	Margate33063	NCT06548542	Map
FL	A Plus Research /ID# 265878	Miami33144	NCT06548542	Map
FL	Nicklaus Children'S Hospital - Miami - Southwest 62nd Avenue /ID# 271585	Miami33155	NCT07071519	Map
FL	Sanchez Clinical Research /ID# 265887	Miami33157	NCT06548542	Map
FL	Sanchez Clinical Research, Inc	Miami33157-6575	NCT07499232	Map
FL	Clinical Site	Miami Gardens33014	NCT06641089	Map
FL	Advanced Research Institute, Inc /ID# 265548	New Port Richey34653	NCT06548542	Map
FL	Hillcrest Medical Research, LLC /ID# 267237	Orange City32763	NCT06548542	Map
FL	Arnold Palmer Hospital for Children Center Digestive Health and Nutrition-Orland /ID# 255437	Orlando32806-1141	NCT05995353	Map
FL	Endoscopic Research, Inc. /ID# 267211	Orlando32803	NCT06548542	Map
FL	HMD Research LLC /ID# 273086	Orlando32819	NCT06865105	Map
FL	West Broward Rheumatology Associates /ID# 272892	Tamarac33321	NCT06865105	Map
FL	AdventHealth Medical Group - Tampa - Bruce B Downs Boulevard /ID# 265538	Tampa33613	NCT06548542	Map
FL	Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 273199	Tampa33606	NCT06865105	Map
FL	Clinical Site	Tampa33607	NCT06641089	Map
FL	GCP Clinical Research	Tampa33609	NCT07499232	Map
FL	Gcp Clinical Research /ID# 278126	Tampa33609	NCT06548542	Map
FL	Clinical Site	Zephyrhills33542	NCT06641089	Map
FL	Florida Medical Clinic - Zephyrhills /ID# 267392	Zephyrhills33542	NCT06548542	Map
GA	Childrens Center For Digestive Health Care /ID# 273228	Atlanta30342	NCT07071519	Map
GA	Clinical Site	Gainesville30501	NCT06641089	Map
GA	Gastroenterology Associates of Central Georgia /ID# 265547	Macon31201	NCT06548542	Map
ID	Treasure Valley Medical Research /ID# 267114	Boise83706	NCT06548542	Map
IL	University of Chicago Medical Center /ID# 267400	Chicago60637	NCT06548542	Map
IL	University of Chicago Medical Center /ID# 271588	Chicago60637	NCT07071519	Map
IL	Northwestern University	Evanston60611	NCT06249555	Map
IL	OSF St. Francis Medical Center /ID# 266973	Peoria61637-0001	NCT06548542	Map
IL	Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879	Skokie60076	NCT06865105	Map
IL	Clinical Site	Springfield62702	NCT06641089	Map
IL	Springfield Clinic Main Campus /ID# 267434	Springfield62703-2403	NCT06548542	Map
IL	Willow Rheumatology and Wellness, PLLC /ID# 277354	Willowbrook60527	NCT06865105	Map
IN	Indiana University Health Riley Hospital for Children /ID# 256454	Indianapolis46202	NCT05995353	Map
IN	Indiana University Health Riley Hospital for Children /ID# 259067	Indianapolis46202	NCT06100744	Map
IN	Indiana University Health University Hospital /ID# 278129	Indianapolis46202	NCT06548542	Map
IA	University of Iowa	Iowa City52242	NCT06249555	Map
KS	Cotton-O'Neil Clinical Research Center	Topeka66606	NCT07499232	Map
KY	University of Kentucky Chandler Medical Center. /ID# 265564	Lexington40536	NCT06548542	Map
LA	Clinical Site	Lake Charles70605	NCT06641089	Map
LA	University Medical Center New Orleans	New Orleans70112	NCT06249555	Map
MD	Clinical Site	Baltimore21224-6821	NCT06641089	Map
MD	Metropolitan Gastroenterology Group - Chevy Chase /ID# 265877	Chevy Chase20815	NCT06548542	Map
MD	Velocity Clinical Research - Rockville /ID# 267712	Rockville20854	NCT06548542	Map
MA	Massachusetts General Hospital /ID# 255767	Boston02114	NCT05995353	Map
MA	Brigham and Women's Hospital	Chestnut Hill02467	NCT06249555	Map
MA	Lucida Clinical Trials /ID# 266548	New Bedford02740	NCT06548542	Map
MI	Clinical Site	Grand Blanc48439-2451	NCT06641089	Map
MI	Henry Ford Medical Center - Columbus /ID# 266503	Novi48377	NCT06548542	Map
MN	M Health Fairview University of Minnesota Medical Center - West Bank /ID# 260111	Minneapolis55454	NCT06100744	Map
MN	MNGI Digestive Health, P. A. /ID# 255366	Minneapolis55413-2195	NCT05995353	Map
MN	Mayo Clinic-Rochester /ID# 265550	Rochester55905	NCT06548542	Map
MO	GI Associates Research, LLC /ID# 267433	Columbia65201	NCT06548542	Map
MO	Bvl Research /ID# 265870	Liberty64068	NCT06548542	Map
MO	Washington University /ID# 266938	St Louis63110	NCT06548542	Map
NV	Vector Clinical Trials /ID# 265561	Las Vegas89128	NCT06548542	Map
NJ	Goryeb Children's Hospital /ID# 271801	Morristown07962	NCT07071519	Map
NJ	Goryeb Childrens Hospital /ID# 256452	Morristown07960	NCT05995353	Map
NY	Clinical Site	Brooklyn11201	NCT06641089	Map
NY	Westchester Putnam Gastroenterology	Carmel10512	NCT07499232	Map
NY	Nyu Langone Long Island Clinical Research Associates - Lake Success /ID# 265566	Lake Success11042	NCT06548542	Map
NY	Columbia University Medical Center /ID# 262587	New York10032-3729	NCT06100744	Map
NY	Icahn School of Medicine at Mount Sinai /ID# 254880	New York10029	NCT05995353	Map
NY	New York Gastroenterology Associates	New York10075	NCT07499232	Map
NY	Northwell Health-Lenox Hill Hospital /ID# 265527	New York10075	NCT06548542	Map
NY	Clinical Site	Rochester14642	NCT06641089	Map
NY	Boston Childrens Health Physicians /ID# 258061	Valhalla10595	NCT06100744	Map
NY	Care Access - Yonkers /ID# 266781	Yonkers10701	NCT06548542	Map
NC	Digestive Health Partners - Biltmore Office /ID# 265539	Asheville28801	NCT06548542	Map
NC	University of North Carolina	Chapel Hill27599	NCT06249555	Map
NC	University of North Carolina - Children's Hospital /ID# 259286	Chapel Hill27514	NCT06100744	Map
NC	Charlotte Gastroenterology and Hepatology, PLLC	Charlotte28207	NCT07499232	Map
NC	Clinical Site	Charlotte28262	NCT06641089	Map
NC	Clinical Site	Leland28451	NCT06641089	Map
NC	Evidera, a PPD Business Unit /ID# 238688	Morrisville27560-7200	NCT04846959	Map
OH	University of Cincinnati /ID# 265589	Cincinnati45267-2827	NCT06548542	Map
OH	Cleveland Clinic - Cleveland /ID# 256453	Cleveland44195	NCT05995353	Map
OH	Cleveland Clinic Foundation	Cleveland44195	NCT06249555	Map
OH	MetroHealth Medical Center /ID# 262377	Cleveland44109	NCT06100744	Map
OH	University Hospitals Cleveland Medical Center /ID# 271831	Cleveland44106	NCT07071519	Map
OH	The Ohio State University /ID# 265577	Columbus43210	NCT06548542	Map
OH	Great Lakes Gastroenterology Research, LLC	Mentor44060	NCT07499232	Map
OH	Clinical Site	Middleburg Heights44130	NCT06641089	Map
OH	Paramount Medical Research and Consulting /ID# 272757	Middleburg Heights44130	NCT06865105	Map
OK	Digestive Disease Specialists - Oklahoma /ID# 265901	Oklahoma City73112	NCT06548542	Map
OK	Digestive Disease Specialists Inc	Oklahoma City73114	NCT07499232	Map
OR	Clinical Site	Portland97239	NCT06641089	Map
OR	OR Clinic - East - GI	Portland97220	NCT06249555	Map
PA	Altoona Center For Clinical Research /ID# 272593	Duncansville16635	NCT06865105	Map
PA	Clinical Site	Duncansville16635	NCT06641089	Map
PA	The Children's Hospital of Philadelphia /ID# 273222	Philadelphia19104	NCT07071519	Map
PA	University of Pennsylvania /ID# 265904	Philadelphia19104	NCT06548542	Map
PA	Upmc Children'S Hospital Of Pittsburgh /ID# 272328	Pittsburgh15224	NCT07071519	Map
PA	Frontier Clinical Research	Uniontown15401	NCT07499232	Map
SC	Patewood Medical Campus /ID# 272477	Greenville29615	NCT07071519	Map
SC	Gastroenterology Associates of Orangeburg /ID# 267548	Orangeburg29118	NCT06548542	Map
SC	Palmetto Primary and Specialty Care Physicians, Charleston	Summerville29486	NCT07499232	Map
TN	Clinical Site	Jackson38305	NCT06641089	Map
TN	GI associates of Northeast Tennessee /ID# 265567	Johnson City37604	NCT06548542	Map
TN	Clinical Site	Memphis38119	NCT06641089	Map
TN	Private Practice - Dr. Ramesh C. Gupta I /ID# 272897	Memphis38119	NCT06865105	Map
TX	Child Neurology Consultants of Austin /ID# 260562	Austin78757-7571	NCT06100744	Map
TX	Clinical Site	Austin78745	NCT06641089	Map
TX	Tekton Research - West Gate /ID# 272765	Austin78745	NCT06865105	Map
TX	Clinical Site	Baytown77521	NCT06641089	Map
TX	Gi Alliance - Cedar Park /ID# 268153	Cedar Park78613	NCT06548542	Map
TX	Clinical Site	Colleyville76034	NCT06641089	Map
TX	GI Alliance Research Fort Worth	Fort Worth76104	NCT06249555	Map
TX	Accurate Clinical Research - Houston /ID# 272754	Houston77089-6142	NCT06865105	Map
TX	Houston Methodist Hospital /ID# 265533	Houston77030	NCT06548542	Map
TX	Caprock Gastro Research - Lubbock - 80th Street /ID# 265541	Lubbock79424	NCT06548542	Map
TX	Clinical Site	Lubbock79424	NCT06641089	Map
TX	GI Alliance Research Mansfield	Mansfield76063	NCT06249555	Map
TX	GI Alliance: Mansfield /ID# 266947	Mansfield76063	NCT06548542	Map
TX	Southern Star Research Institute /ID# 278124	San Antonio78229	NCT06548542	Map
TX	Southern Star Research Institute, LLC	San Antonio78229	NCT07499232	Map
TX	Sun Research Institute /ID# 266723	San Antonio78215	NCT06548542	Map
TX	Tekton Research, LLC /ID# 272901	San Antonio78251	NCT06865105	Map
TX	Dynamed Clinical Research - Tomball /ID# 272760	Tomball77375	NCT06865105	Map
TX	Tyler Research Institute /ID# 265545	Tyler75701	NCT06548542	Map
UT	Care Access - Ogden /ID# 266428	Ogden84403	NCT06548542	Map
WA	GI Alliance - Bellevue - Washington Gastroenterology	Bellevue98004	NCT06249555	Map
WA	Clinical Site	Seattle98122	NCT06641089	Map
WA	Virginia Mason Hospital & Medical Center /ID# 265574	Seattle98101	NCT06548542	Map
WA	Washington Gastroenterology - Tacoma /ID# 267302	Tacoma98405	NCT06548542	Map
WV	Clinical Site	Beckley25801	NCT06641089	Map

Risankizumab clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	completed	terminated	withdrawn	not yet recruiting	no longer available	Total
P1			15	1		1		17
P1/P2	1					1		2
P2	2		12			1		15
P2/P3			1					1
P3	5	9	18			1		33
P4	1		6			1		8
N/A	3				1	1	1	6

Recruiting Risankizumab clinical trials (18)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT07071519	MIGHTYA Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis	P3	Ulcerative Colitis	120	Jul 2025
NCT04846959	Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications	—	Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment	818	Jul 2021
NCT07448402	Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease	—	Psoriasis	50	May 2026
NCT07499232	CHARGEA Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease	P3	Crohn Disease	530	Apr 2026
NCT07352566	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	P4	Psoriasis	10	Aug 2026
NCT06548542	Target CDStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease	P2	Crohn's Disease	540	Sep 2024
NCT05995353	RISEA Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease	P3	Crohn's Disease	110	Dec 2023
NCT05928039	PATHFINDERPATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease	P4	Crohn Disease	297	Oct 2023
NCT06100744	A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab	P3	Juvenile Psoriatic Arthritis	40	Jul 2024
NCT07177118	Risankizumab for Fibrostenotic Crohn's Disease Treatment	P3	Crohn Disease	260	Oct 2025
NCT07258641	VOYAGERFluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease	P1/P2	Ulcerative Colitis (UC)	30	Jan 2026
NCT06865105	Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis	P2	Psoriatic Arthritis	120	Apr 2025
NCT07138898	Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty	P2	Rheumatic Disease	80	Sep 2025
NCT07466550	A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants	P1	Healthy Volunteer	60	Mar 2026
NCT06641089	IZAR-2Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response	P3	Arthritis, Psoriatic	600	Oct 2024
NCT06249555	VOICEVOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study	—	Crohn's Disease	300	Mar 2024
NCT06298188	Risankizumab in Children With Crohn's Disease (RisaKids)	N/A	Crohn Disease	90	Oct 2024
NCT06606808	NAVIGATEFluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease	P1/P2	Ulcerative Colitis (UC)	18	Nov 2024

Risankizumab clinical trials by indication

Psoriasis (25)

NCT	Acronym	Phase	Status	Title
NCT07448402	—	N/A	not yet recruiting	Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
NCT07352566	—	P4	not yet recruiting	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT04862286	OptIMMize-2	P3	active not recruiting	Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
NCT04630652	—	P4	completed	Risankizumab Long-term Remission Study
NCT04340076	BeNeBio	P4	completed	Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
NCT04435600	OptIMMize-1	P3	completed	A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
NCT05283135	KNOCKOUT	P2	completed	High Dose Risankizumab for Psoriasis
NCT03047395	LIMMITLESS	P3	completed	A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
+ 17 more, see All trials below.

Healthy Volunteers (12)

NCT	Acronym	Phase	Status	Title
NCT07007091	—	P1	completed	A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants
NCT06946524	—	P1	completed	A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants
NCT06571266	—	P1	completed	A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants
NCT06487572	—	P1	completed	A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
NCT06054425	—	P1	completed	A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults
NCT05567029	—	P1	completed	Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers.
NCT05274100	—	P1	completed	Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
NCT05274087	AI	P1	completed	Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers
+ 4 more, see All trials below.

Crohn's Disease (8)

NCT	Acronym	Phase	Status	Title
NCT06548542	Target CD	P2	recruiting	Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT05995353	RISE	P3	recruiting	A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT06063967	AFFIRM	P3	active not recruiting	A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06249555	VOICE	N/A	recruiting	VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
NCT03105102	FORTIFY	P3	active not recruiting	A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
NCT03104413	—	P3	completed	A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
NCT03105128	—	P3	completed	A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03914261	—	N/A	no longer available	Expanded Access to Risankizumab

Crohn Disease (6)

NCT	Acronym	Phase	Status	Title
NCT07499232	CHARGE	P3	recruiting	A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05928039	PATHFINDER	P4	recruiting	PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
NCT07177118	—	P3	not yet recruiting	Risankizumab for Fibrostenotic Crohn's Disease Treatment
NCT06298188	—	N/A	recruiting	Risankizumab in Children With Crohn's Disease (RisaKids)
NCT02513459	—	P2	completed	A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
NCT02031276	—	P2	completed	Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.

Ulcerative Colitis (UC) (5)

NCT	Acronym	Phase	Status	Title
NCT03398135	COMMAND	P3	active not recruiting	A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT07258641	VOYAGER	P1/P2	not yet recruiting	Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease
NCT06606808	NAVIGATE	P1/P2	recruiting	Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease
NCT03398148	—	P2/P3	completed	A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04254783	IV	P1	completed	A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Psoriatic Arthritis (4)

NCT	Acronym	Phase	Status	Title
NCT06865105	—	P2	recruiting	Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
NCT03675308	KEEPsAKE 1	P3	active not recruiting	A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
NCT06624228	—	P3	active not recruiting	A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
NCT02986373	NCT02719171	P2	completed	A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)

Arthritis, Psoriatic (3)

NCT	Acronym	Phase	Status	Title
NCT06641089	IZAR-2	P3	recruiting	Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
NCT05083078	—	P1	terminated	A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis
NCT02719171	—	P2	completed	BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis

Healthy Volunteer (2)

NCT	Acronym	Phase	Status	Title
NCT07466550	—	P1	not yet recruiting	A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants
NCT06937619	—	P1	completed	A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants

Ulcerative Colitis (2)

NCT	Acronym	Phase	Status	Title
NCT07071519	MIGHTY	P3	recruiting	A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT06880744	REVAMP	P3	active not recruiting	A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

Rheumatic Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07138898	—	P2	not yet recruiting	Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Juvenile Psoriatic Arthritis (1)

NCT	Acronym	Phase	Status	Title
NCT06100744	—	P3	recruiting	A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Moderate Plaque Psoriasis (1)

NCT	Acronym	Phase	Status	Title
NCT06333860	IMMpactful	P4	completed	A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

Inflammatory Bowel Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06346288	—	P4	completed	A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease

Genital Psoriasis (1)

NCT	Acronym	Phase	Status	Title
NCT05969223	UnlIMMited	P4	completed	Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment (1)

NCT	Acronym	Phase	Status	Title
NCT04846959	—	N/A	recruiting	Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

COVID-19 (1)

NCT	Acronym	Phase	Status	Title
NCT04583956	BET-A	P2	completed	ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19

Crohn's Disease (CD) (1)

NCT	Acronym	Phase	Status	Title
NCT04524611	SEQUENCE	P3	active not recruiting	Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

Palmoplantar Pustulosis (PPP) (1)

NCT	Acronym	Phase	Status	Title
NCT04451720	—	P3	completed	Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis

Plaque Psoriasis (1)

NCT	Acronym	Phase	Status	Title
NCT04102007	—	P3	completed	A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

Hidradenitis Suppurativa (1)

NCT	Acronym	Phase	Status	Title
NCT03926169	DETERMINED 1	P2	completed	A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Psoriatic Arthritis (PsA) (1)

NCT	Acronym	Phase	Status	Title
NCT03671148	KEEPsAKE2	P3	active not recruiting	A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

Dermatitis (1)

NCT	Acronym	Phase	Status	Title
NCT03706040	—	P2	completed	A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Asthma (1)

NCT	Acronym	Phase	Status	Title
NCT02443298	—	P2	completed	Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma

Ankylosing Spondylitis (AS) (1)

NCT	Acronym	Phase	Status	Title
NCT02047110	AS	P2	completed	BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)

Risankizumab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
PATHFINDER	NCT05928039	P4	recruiting	Crohn Disease	297	—
IMMpactful	NCT06333860	P4	completed	Moderate Plaque Psoriasis	393	—
UnlIMMited	NCT05969223	P4	completed	Genital Psoriasis	214	PMID 41139175
BeNeBio	NCT04340076	P4	completed	Psoriasis	244	PMID 34656148
MIGHTY	NCT07071519	P3	recruiting	Ulcerative Colitis	120	—
CHARGE	NCT07499232	P3	recruiting	Crohn Disease	530	—
RISE	NCT05995353	P3	recruiting	Crohn's Disease	110	—
COMMAND	NCT03398135	P3	active not recruiting	Ulcerative Colitis (UC)	1,242	PMID 40168091
REVAMP	NCT06880744	P3	active not recruiting	Ulcerative Colitis	573	—
OptIMMize-2	NCT04862286	P3	active not recruiting	Psoriasis	132	—
SEQUENCE	NCT04524611	P3	active not recruiting	Crohn's Disease (CD)	527	PMID 39018531
AFFIRM	NCT06063967	P3	active not recruiting	Crohn's Disease	289	—
IZAR-2	NCT06641089	P3	recruiting	Arthritis, Psoriatic	600	—
KEEPsAKE 1	NCT03675308	P3	active not recruiting	Psoriatic Arthritis	964	PMID 34911706
KEEPsAKE2	NCT03671148	P3	active not recruiting	Psoriatic Arthritis (PsA)	444	PMID 34815219
FORTIFY	NCT03105102	P3	active not recruiting	Crohn's Disease	1,336	PMID 36917429
OptIMMize-1	NCT04435600	P3	completed	Psoriasis	139	—
LIMMITLESS	NCT03047395	P3	completed	Psoriasis	2,170	PMID 34157132
IMMprint	NCT04713592	P3	completed	Psoriasis	174	—
IMMPRESS	NCT03518047	P3	completed	Psoriasis	50	PMID 35917057
Target CD	NCT06548542	P2	recruiting	Crohn's Disease	540	—
KNOCKOUT	NCT05283135	P2	completed	Psoriasis	20	—
BET-A	NCT04583956	P2	completed	COVID-19	214	PMID 34473343
DETERMINED 1	NCT03926169	P2	completed	Hidradenitis Suppurativa	243	PMID 36892753
NCT02719171	NCT02986373	P2	completed	Psoriatic Arthritis	145	—
AS	NCT02047110	P2	completed	Ankylosing Spondylitis (AS)	159	PMID 29945918

Terminated and withdrawn Risankizumab trials (2)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT05083078terminatedA Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis
NCT04799990withdrawnStudy to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

All Risankizumab trials (82)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT07071519	MIGHTY	A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis	P3	recruiting	120	AbbVie	Jul 2025
NCT04846959		Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications	—	recruiting	818	AbbVie	Jul 2021
NCT07448402		Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease	—	not yet recruiting	50	Caja Costarricense de Seguro Social	May 2026
NCT07499232	CHARGE	A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease	P3	recruiting	530	Janssen Research & Development, LLC	Apr 2026
NCT07352566		Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	P4	not yet recruiting	10	University of California, San Francisco	Aug 2026
NCT06548542	Target CD	Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease	P2	recruiting	540	AbbVie	Sep 2024
NCT05995353	RISE	A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease	P3	recruiting	110	AbbVie	Dec 2023
NCT03398135	COMMAND	A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis	P3	active not recruiting	1,242	AbbVie	Aug 2018
NCT05928039	PATHFINDER	PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease	P4	recruiting	297	University of Calgary	Oct 2023
NCT06100744		A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab	P3	recruiting	40	AbbVie	Jul 2024
NCT07177118		Risankizumab for Fibrostenotic Crohn's Disease Treatment	P3	not yet recruiting	260	First Affiliated Hospital of Wenzhou Medical University	Oct 2025
NCT06880744	REVAMP	A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab	P3	active not recruiting	573	AbbVie	Jun 2025
NCT04862286	OptIMMize-2	Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977	P3	active not recruiting	132	AbbVie	Jul 2021
NCT07258641	VOYAGER	Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease	P1/P2	not yet recruiting	30	University Medical Center Groningen	Jan 2026
NCT04524611	SEQUENCE	Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)	P3	active not recruiting	527	AbbVie	Sep 2020
NCT06865105		Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis	P2	recruiting	120	AbbVie	Apr 2025
NCT07138898		Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty	P2	not yet recruiting	80	NYU Langone Health	Sep 2025
NCT06063967	AFFIRM	A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.	P3	active not recruiting	289	AbbVie	Nov 2023
NCT07466550		A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants	P1	not yet recruiting	60	AbbVie	Mar 2026
NCT06641089	IZAR-2	Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response	P3	recruiting	600	MoonLake Immunotherapeutics AG	Oct 2024
NCT06249555	VOICE	VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study	—	recruiting	300	Alimentiv Inc.	Mar 2024
NCT06298188		Risankizumab in Children With Crohn's Disease (RisaKids)	N/A	recruiting	90	Shaare Zedek Medical Center	Oct 2024
NCT03675308	KEEPsAKE 1	A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	P3	active not recruiting	964	AbbVie	Mar 2019
NCT03671148	KEEPsAKE2	A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)	P3	active not recruiting	444	AbbVie	Mar 2019
NCT06624228		A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis	P3	active not recruiting	684	UCB Biopharma SRL	Oct 2024
NCT03105102	FORTIFY	A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease	P3	active not recruiting	1,336	AbbVie	Apr 2018
NCT06333860	IMMpactful	A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)	P4	completed	393	AbbVie	May 2024
NCT06346288		A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease	P4	completed	10	AbbVie	Apr 2024
NCT07007091		A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants	P1	completed	260	AbbVie	Jun 2025
NCT06606808	NAVIGATE	Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease	P1/P2	recruiting	18	University Medical Center Groningen	Nov 2024
NCT05969223	UnlIMMited	Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis	P4	completed	214	AbbVie	Aug 2023
NCT06946524		A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants	P1	completed	59	AbbVie	May 2025
NCT06937619		A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants	P1	completed	263	AbbVie	Apr 2025
NCT04630652		Risankizumab Long-term Remission Study	P4	completed	24	Jaehwan Kim	Apr 2021
NCT06571266		A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants	P1	completed	231	AbbVie	Sep 2024
NCT06487572		A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants	P1	completed	60	AbbVie	Jul 2024
NCT04340076	BeNeBio	Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis	P4	completed	244	Radboud University Medical Center	Aug 2020
NCT04435600	OptIMMize-1	A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms	P3	completed	139	AbbVie	Jul 2020
NCT05283135	KNOCKOUT	High Dose Risankizumab for Psoriasis	P2	completed	20	Oregon Medical Research Center	Mar 2022
NCT06054425		A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults	P1	completed	48	AbbVie	Nov 2023
NCT03047395	LIMMITLESS	A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )	P3	completed	2,170	AbbVie	Feb 2017
NCT03398148		A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis	P2/P3	completed	1,558	AbbVie	Mar 2018
NCT05567029		Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers.	P1	completed	198	AbbVie	Sep 2022
NCT04908475		Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy	P4	completed	352	AbbVie	Jun 2021
NCT04713592	IMMprint	Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement	P3	completed	174	AbbVie	Feb 2021
NCT04451720		Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis	P3	completed	119	AbbVie	Jul 2020
NCT04102007		A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab	P3	completed	244	AbbVie	Nov 2019
NCT04254783	IV	A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease	P1	completed	20	AbbVie	May 2020
NCT05083078		A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis	P1	terminated	11	Janssen Research & Development, LLC	Nov 2021
NCT04799990		Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting	—	withdrawn	0	AbbVie	Jun 2021
NCT03219437		A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis	P3	completed	104	AbbVie	Jul 2018
NCT04583956	BET-A	ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19	P2	completed	214	National Institute of Allergy and Infectious Diseases (NIAID)	Oct 2020
NCT03926169	DETERMINED 1	A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	P2	completed	243	AbbVie	Jun 2019
NCT05274100		Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants	P1	completed	394	AbbVie	Sep 2020
NCT03104413		A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment	P3	completed	618	AbbVie	Dec 2017
NCT03706040		A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis	P2	completed	172	AbbVie	Dec 2018
NCT03105128		A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease	P3	completed	931	AbbVie	May 2017
NCT05274087	AI	Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers	P1	completed	30	AbbVie	Sep 2020
NCT03022045		A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis	P3	completed	18	AbbVie	Jan 2017
NCT03875508		A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis	P3	completed	108	AbbVie	Jun 2019
NCT03875482		A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis	P3	completed	157	AbbVie	May 2019
NCT03478787		Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis	P3	completed	327	AbbVie	May 2018
NCT05268068	IV	A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China	P1	completed	30	AbbVie	Jun 2019
NCT03518047	IMMPRESS	Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation	P3	completed	50	AbbVie	Jul 2018
NCT05283681		A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants	P1	completed	226	AbbVie	Apr 2019
NCT02513459		A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease	P2	completed	65	AbbVie	Sep 2015
NCT03914261		Expanded Access to Risankizumab	—	no longer available	0	AbbVie	—
NCT02203851		Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis	P2	completed	110	AbbVie	Nov 2014
NCT02986373	NCT02719171	A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)	P2	completed	145	AbbVie	Dec 2016
NCT02672852		BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment	P3	completed	507	AbbVie	Feb 2016
NCT03255382		A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy	P3	completed	120	AbbVie	Aug 2017
NCT03000075		BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis	P2	completed	182	AbbVie	Dec 2016
NCT05305222		A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab	P1	completed	17	AbbVie	Oct 2017
NCT05283694		A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants	P1	completed	48	AbbVie	Sep 2017
NCT02443298		Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma	P2	completed	214	AbbVie	Jun 2015
NCT02684357		BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis	P3	completed	577	AbbVie	Mar 2016
NCT02684370		BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis	P3	completed	560	AbbVie	Feb 2016
NCT02772601		This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis	P1	completed	21	AbbVie	Sep 2016
NCT02719171		BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis	P2	completed	185	AbbVie	Apr 2016
NCT02694523		BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis	P3	completed	684	AbbVie	Mar 2016
NCT02031276		Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.	P2	completed	121	AbbVie	Feb 2014
NCT02047110	AS	BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)	P2	completed	159	AbbVie	Jan 2014

Risankizumab clinical trials: frequently asked questions

How many Risankizumab clinical trials are there?: 82 Risankizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 12 are actively recruiting participants. 52 are marked completed.
Are Risankizumab clinical trials recruiting in 2026?: Yes — 12 Risankizumab trials are actively recruiting in 2026, with 170 U.S. sites across 35 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Risankizumab being studied for?: Risankizumab is being studied for Psoriasis, Healthy Volunteers, Crohn's Disease, Ulcerative Colitis (UC), Crohn Disease and 27 more. The trials are grouped by indication on this page.
What phase is Risankizumab in?: Risankizumab clinical trials span 8 Phase 4, 33 Phase 3, 15 Phase 2, 17 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Risankizumab clinical trials?: The lead sponsor across the most Risankizumab trials is AbbVie, with 15 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Risankizumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 18, 2026.

Related pages on Hipa.ai:

Risankizumab overview Risankizumab evidence & publications